A Randomized, Double-blinded, Active-controlled Phase II Clinical Study to Evaluate the Immunogenicity and Safety of SCTV01C (A Bivalent SARS-CoV-2 Trimeric Spike Protein Vaccine) and SCTV01E (A COVID-19 Alpha/Beta/Delta/Omicron Variants S-Trimer Vaccine) in Population Aged ≥12 Years and Previously Unvaccinated
Latest Information Update: 14 Feb 2024
At a glance
Most Recent Events
- 07 Feb 2024 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 13 Apr 2022 New trial record